

Osta Biotechnologies Inc.  
Press Release  
For Immediate Distribution

## **OSTA'S CANCER TECHNOLOGY PUBLISHED IN A PRESTIGIOUS JOURNAL**

**MONTREAL, QC – October 21, 2009** - Osta Biotechnologies Inc. today announced that the journal Cancer Research, a high impact publication of the American Association of Cancer Research has published a paper in its October 15, 2009 issue containing the data on Osta's novel anti-cancer therapeutic approach and has selected the paper to appear as a highlight. The results summarized in this paper identify Heme Oxygenase-1 (HO-1) as a potential biomarker and therapeutic target for hormone refractory prostate cancer (HRPCA).

The article entitled "A novel experimental Heme Oxygenase-1 targeted therapy for hormone-refractory prostate cancer" is accessible online and can be found at [www.cancerres.aacrjournals.org](http://www.cancerres.aacrjournals.org).

The results contained in this publication demonstrate augmented HO-1 expression in HRPCA tissue relative to hormone-responsive PCA and benign disease. HO-1 gene silencing in HRPCA cells, or exposure of HRPCA cells to Osta's lead small molecule inhibitor of HO-1, significantly reduced cell invasion *in vitro* and tumor growth & metastasis formation in animal models. These results highlight the clinical potential of targeting HO-1 in cancer.

Dr. Ajay Gupta, Chairman & CEO of Osta commented "The selection of this paper as a highlight in this prestigious journal validates the solid science behind our cancer therapeutic program directed towards the development of novel HO-1 inhibitors to treat advanced cancers."

The company also announced that it is currently focusing on the development of a novel drug for cancer and Alzheimer's disease and has therefore, terminated a license agreement with McGill University that covers the osteoporosis diagnostic test technology. This diagnostic technology constitutes a non-core asset of the company and is not of any interest to the company given its current research focus on therapeutics development.

### ***Osta Biotechnologies Inc.***

Osta is a biopharmaceutical company listed on the TSX Venture Exchange (TSXV: OBI) dedicated to developing novel diagnostics and therapeutics for the aging population particularly in the areas of Cancer, Alzheimer's disease, Osteoporosis, Osteoarthritis and XLH.

For further information, please contact:

Osta Biotechnologies Inc.  
Dr. Ajay Gupta  
Chairman & CEO  
(514) 626-9519

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

*Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.*

The issue of this press release is limited to Canada only. This press release should not be issued in the United States through U.S. news wire agencies.